Fluocinolone Acetonide Implant Effective for Refractory Diabetic Macular Edema
10/03/2018
Most patients with chronic diabetic macular edema (DME) who received a fluocinolone acetonide intravitreal implant did not require additional therapy to lower their intraocular pressure (IOP), according to a registry safety study of the implant (Iluvien, Alimera Sciences), according to a Reuters report.
Earlier treatment with the 0.2 ug/day fluocinolone acetonide (FAc) implant was associated with better outcomes in terms of both IOP and visual acuity, researchers reported online September 21 in the British Journal of Ophthalmology.